---
title: 'Scientist I, Bioanalytical – Drug Antibody Conjugates (DACs) at Nurix'
canonical: 'https://feeny.ai/job/scientist-i-bioanalytical-drug-antibody-conjugates-dacs-nurix-brisbane-hf08c41xt7tb'
type: 'job'
last_seen: '2026-09-09'
---

# Scientist I, Bioanalytical – Drug Antibody Conjugates (DACs) at Nurix

- **Company:** Nurix
- **Location:** Brisbane, CA
- **Posted:** 2026-08-05
- **Last confirmed live:** 2026-09-09
- **Apply:** https://job-boards.greenhouse.io/nurix/jobs/8684692002

## Job description

Scientist I, Bioanalytical – Drug Antibody Conjugates (DACs)

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease.

Position:

Nurix Therapeutics is seeking a Scientist to lead bioanalytical strategies supporting the discovery and development of next-generation degrader antibody conjugates (DACs). This role will focus on LC-MS/MS and hybrid assay strategies for quantitative and qualitative analysis of complex bioconjugates across in vitro and in vivo studies to understand DAC pharmacokinetics, pharmacodynamics, and biotransformation.

The successful candidate will operate at the interface of small and large molecule bioanalysis, and will contribute to assay development, method qualification, and execution, applying advanced LC-MS/MS and hybrid approaches to support in vitro and in vivo studies across discovery and early development

Key Responsibilities:

- Lead the development, qualification, and execution of bioanalytical methods for DAC modalities, including intact conjugates, total antibody, conjugated payload, and released degrader species in complex biological matrices.
- Design and implement LC-MS/MS-based workflows using Sciex platforms for sensitive and selective quantitation of small molecule payloads, linker-derived species, and catabolites
- Apply high-resolution mass spectrometry platforms for DAC characterization and metabolite identification
- Develop hybrid LBA–LC-MS/MS strategies to address challenges in conjugate quantitation and differentiation of molecular species.
- Design, execute and interpret in vitro studies, including plasma and lysosomal stability, linker cleavage kinetics, protease-mediated processing, and degradation assays.
- Lead bioanalytical support for in vivo studies, including PK, tissue distribution, and tumor exposure in preclinical species integrating DAC components to inform exposure-response relationships.
- Characterize biotransformation pathways of DACs, including identification of linker cleavage products, payload metabolites, and antibody modifications.
- Partner closely with DMPK, Proteomics, Pharmacology and Chemistry teams to inform molecular design through data-driven insights on stability, exposure, and degradation efficiency.
- Author and review technical reports, regulatory documentation, and study summaries with a high level of scientific rigor and clarity.
- Troubleshoot analytical challenges related to matrix effects, low-level quantitation, and conjugate heterogeneity.
- Mentor junior scientists and contribute to building bioanalytical capabilities and best practices within the organization.
- Evaluate and implement emerging technologies to advance characterization of targeted protein degrader modalities.
- Lead the identification, selection, and oversight of contract research organizations (CROs) for bioanalytical method development, assay transfer, and phase‑appropriate qualification.

Preferred Qualifications & Experience:

- Experience in targeted protein degradation or heterobifunctional degrader platforms.
- Experience with hybrid LBA–LC-MS/MS assays and ligand-binding assays (ELISA, MSD).
- Understanding of linker chemistry, conjugation strategies, and degradation mechanisms for bioconjugates.
- Exposure to regulatory bioanalytical guidance (FDA, EMA) for large molecules and conjugates.

Requirements:

- Ph.D. with 5+ years or M.S. with 8+ years of relevant industry experience in Bioanalysis, Analytical chemistry, or related field.
- Deep expertise in LC-MS/MS bioanalysis, including method development, qualification/validation, and troubleshooting for complex modalities.
- Proven experience with Sciex platforms (e.g., 7600 ZenoTOF, 6500+, 7500) and high-resolution MS.
- Strong background in ADCs, DACs, or related bioconjugates, including characterization and payload quantitation.
- Experience supporting both in vitro ADME and in vivo PK studies, with demonstrated ability to interpret integrated datasets.
- Proficiency in sample preparation techniques for large molecules and bioconjugates (e.g., immunocapture, enzymatic digestion, hybrid workflows).
- Strong data analysis, visualization, and reporting skills (e.g., vendor software, GraphPad Prism).
- Excellent written and verbal communication skills, with experience in technical documentation.
- Ability to work in a fast-paced, collaborative environment and manage multiple priorities.

Fit with Nurix Culture and Values

- Strong team orientation; highly collaborative
- Solutions and results-oriented focus
- Hands-on approach; resourceful and open to diverse points of view

Salary Range:   $123,800 - $143,100

Location:         Brisbane, CA - Onsite

## About Nurix

## Company Overview
- **One-liner**: Nurix Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation medicines to outmatch disease by harnessing the cell’s natural protein disposal system.
- **Entity Type**: Public (NASDAQ: NRIX)
- **Headquarters**: San Francisco, California, USA
- **Founded**: 2009
- **Founders**: Not publicly listed as individual founders; the company was spun out from research at UC Berkeley and UC San Francisco.

## Core Business
- **Primary industry**: Biopharmaceuticals / Targeted Protein Degradation
- **Target customers**: B2B (pharma partners) and B2C (patients via clinical trials and eventual commercial therapies); enterprise-level partnerships with major pharma.
- **Mission or purpose statement**: "Writing medicine’s next chapter using targeted protein degradation as a new script to outmatch disease." [nurixtx.com](https://www.nurixtx.com/)

## Products & Services
- **Bexobrutideg (NX-5948)**: A potential best-in-class BTK degrader in Phase 1b/2 clinical trials for relapsed/refractory CLL/SLL and chronic spontaneous urticaria. Co-developed and co-commercialized with Roche under a global collaboration announced June 2026. [nurixtx.com](https://www.nurixtx.com/)
- **NX-2127**: A BTK degrader in clinical development for B-cell malignancies.
- **CBL-B Inhibitor (NX-1607)**: An E3 ligase inhibitor designed to activate T cells for immuno-oncology, in Phase 1 clinical trials.
- **IRAK4 Degrader**: A partnered program with Gilead in Phase 1 for inflammatory diseases.
- **STAT6 Degrader**: A partnered program with Sanofi in IND-enabling studies.
- **DEL-AI Discovery Engine**: A proprietary, fully AI-integrated platform combining DNA-encoded libraries (DEL), automated chemistry, and machine learning to design and optimize targeted protein degraders and degrader-antibody conjugates (DACs).

## Market Standing
- **Valuation/Market Cap**: Not publicly available in the provided search results; as a public company (NRIX), market cap fluctuates daily. Check financial platforms for the latest figure.
- **Key Metric**: Annual Revenue (public) — Not publicly available in the provided search results; as a clinical-stage biotech, revenue is typically minimal or pre-revenue. Total funding raised prior to IPO is not detailed in the provided results.
- **Notable Investors/Partners**: Roche (global co-development and co-commercialization collaboration for bexobrutideg, announced June 2026), Gilead (partnered IRAK4 degrader program), Sanofi (partnered STAT6 degrader program).
- **Growth Signals**: Announced a landmark global collaboration with Roche in June 2026 to co-develop and co-commercialize bexobrutideg across malignant hematology, immunology, and neurology. Presented positive Phase 1a/b data for bexobrutideg in CLL/SLL and chronic spontaneous urticaria in 2026. Multiple partnered and wholly owned pipeline programs advancing through clinical and preclinical stages.

## Competitive Advantages
- **Proprietary DEL-AI Discovery Engine**: A fully AI-integrated platform combining DNA-encoded libraries, automated chemistry, and machine learning to design degraders against any protein class, providing a significant speed and innovation advantage. [nurixtx.com](https://www.nurixtx.com/)
- **Unparalleled Ligase Expertise**: Deep understanding of E3 ligase biochemistry and biology, a critical and complex component of the protein degradation mechanism, giving them a unique moat.
- **Multi-Modal Pipeline**: Developing both small molecule degraders and Degrader-Antibody Conjugates (DACs), expanding the therapeutic reach and creating multiple shots on goal.
- **Strong Partnership Network**: Collaborations with top-tier pharma (Roche, Gilead, Sanofi) validate their platform and provide non-dilutive funding and shared risk.

## Strategic Focus
- **Clinical Advancement**: Driving lead asset bexobrutideg through pivotal trials in CLL/SLL and expanding into immunology (chronic spontaneous urticaria) and neurology.
- **Platform Expansion**: Leveraging the DEL-AI engine to develop Degrader-Antibody Conjugates (DACs) for enhanced cell specificity and safety.
- **Pipeline Breadth**: Advancing a multi-modal pipeline across oncology, immunology, and neurology, both wholly owned and through strategic partnerships.
- **Partnership Leverage**: Deepening collaborations with Roche, Gilead, and Sanofi to co-develop and co-commercialize programs, reducing risk and accelerating timelines.

## Why Work Here
- **Culture**: Mission-focused, values-based, and spirited culture emphasizing "breakthrough innovation," "leadership," "accountability," and "zealousness." Employees are encouraged to "think big and act bold." [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
- **Work with Industry Leaders**: The team includes scientific innovators who built the protein degradation field, seasoned executives with biotech scaling expertise, and leading clinicians. [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
- **Growth & Impact**: Employees can "wear many hats" and gain broad exposure in a lean, virtual drug developer environment. The company emphasizes career growth and opportunity-rich experiences.
- **Work Policy**: Onsite in Brisbane, CA (San Francisco Bay Area) for most roles, as indicated by job postings. [nurixtx.com](https://www.nurixtx.com/explore-jobs/)
- **Benefits**: Comprehensive health and welfare plans, enhanced parental leave, wellness reimbursement, 401(k) employer match, and a highly collaborative culture. [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
- **Engineering/Science Culture**: Described as "mission-focused, values-based, and spirited," with a focus on "intellectual and technical ingenuity" and "intelligent risk-taking." The company is a "virtual drug developer" with a lean internal infrastructure, relying on SaaS and cloud platforms. [nurixtx.com](https://www.nurixtx.com/explore-jobs/)

## Sources
1. [nurixtx.com](https://www.nurixtx.com/)
2. [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
3. [nurixtx.com](https://www.nurixtx.com/explore-jobs/)
4. [nurixtx.com](https://www.nurixtx.com/our-story/)

## Other roles at Nurix

- [Associate Director, electronic Quality Management System (eQMS)](https://feeny.ai/job/associate-director-electronic-quality-management-system-eqms-nurix-brisbane-k35rdgj6th4k) — Brisbane, CA
- [Director, Nonclinical Toxicology Operations](https://feeny.ai/job/director-nonclinical-toxicology-operations-nurix-brisbane-california-a7ynjr847xvh) — Brisbane California, United States
- [Director, Medical Affairs - Immunology](https://feeny.ai/job/director-medical-affairs-immunology-nurix-brisbane-california-8q3w67dea5xq) — Brisbane California, United States
- [Senior Manager/Associate Director, Regulatory Affairs (Strategy, Hematology Oncology)](https://feeny.ai/job/senior-manager-associate-director-regulatory-affairs-strategy-hematology-zsgdf1qycbew) — Brisbane California, United States
- [Senior Administrative Assistant, R&ED](https://feeny.ai/job/senior-administrative-assistant-r-ed-nurix-brisbane-california-9k9rhmyvd955) — Brisbane California, United States
- [Senior Director, Quality Control](https://feeny.ai/job/senior-director-quality-control-nurix-brisbane-california-d4hqe06vb3t7) — Brisbane California, United States
- [Associate Director, Chemical Engineering](https://feeny.ai/job/associate-director-chemical-engineering-nurix-brisbane-california-6gbpc8ben8eh) — Brisbane California, United States
- [Senior Analyst, FP&A](https://feeny.ai/job/senior-analyst-fp-a-nurix-brisbane-california-g7qxkkvsfwbf) — Brisbane California, United States
- [Medical Director / Senior Medical Director](https://feeny.ai/job/medical-director-senior-medical-director-nurix-brisbane-california-wkgs5dx1e7eq) — Brisbane California, United States
- [Medical Director / Senior Medical Director](https://feeny.ai/job/medical-director-senior-medical-director-nurix-brisbane-california-57ydhjmqgfm6) — Brisbane California, United States